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Abstract
Objective: Fragile X syndrome is the most common inherited form of 
X-linked mental retardation (XLMR). The aim of this study was to screen 
for and identify fragile X syndrome-affected individuals using DNA-based 
molecular approaches at a special education school for the mentally 
retarded in Hualien, Taiwan.
Materials and Methods: Genomic DNA extracted from 217 individuals with 
mental retardation, including 148 males and 69 females, was analyzed 
using polymerase chain reaction, DNA gel electrophoresis and Southern 
blot analysis. Individuals with the full mutation or premutation were deter-
mined according to the CGG repeat size in the 5’-untranslated region in the 
FMR1 gene on chromosome Xq27.3.
Results: A total of 217 individuals with mental retardation were screened, 
and three (1.38%) were identified as having fragile X full mutation. Two of 
the 148 males (1.35%) and one of the 69 females (1.44%) had this mutation. 
The incidence is very close to that in previous reports in Western Taiwan. 
Female carriers of fragile X syndrome were not found in this study.
Conclusion: We established a molecular screening approach and report 
the incidence of fragile X syndrome in a mentally retarded population in 
Eastern Taiwan. The molecular study and genetic counseling for other family 
members will continue in the future. [Tzu Chi Med J 2008;20(4):309–313]
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1. Introduction
Fragile X syndrome (OMIM: 309550), existence of cyto-
genetic fragile site on Xq27.3, is the most common 
form of X-linked mental retardation (XLMR) [1]. It has 
been noted that fragile X syndrome is an inherited 
mental retardation disorder, and is the second most 
identifiable cause of mental retardation after Down 
syndrome. The frequency of fragile X syndrome in 
males is estimated to be 1 in 4000 [2,3]. Affected males 
with fragile X syndrome usually have an IQ range of 
20–70. Other clinical features include a long narrow 
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face, prominent ears and jaw, macroorchidism, flat 
feet and autistic behavior [4–6].
Fragile X syndrome is caused by a CGG-repeated 
expansion within the 5 untranslated region (5-UTR) 
of the fragile X mental retardation 1 (FMR1) gene on 
the q arm of the X chromosome [7]. The number of 
trinucleotide repeats in the population is classified as 
normal, premutation, and full mutation. The normal 
CGG repeat size is polymorphic below 54. Asympto-
matic fragile X carriers have a repeat size ranging 
from 55 to 200, which is termed premutation. When 
the trinucleotide expansion length exceeds 200 re-
peats in affected individuals, it is termed full mutation 
of the FMR1 gene [3,8,9]. It is now known that in CGG 
repeats expanded to full mutation length, hyper-
methylation of the CpG islands in the promoter region 
of the FMR1 gene occurs and gene expression is 
silenced. The transcriptional inactivation of the FMR1 
gene leads to absence of protein product and devel-
opment of the phenotype of fragile X syndrome [4,10]. 
Identification of the size of the CGG repeat is the 
basis of molecular testing for fragile X syndrome.
To date, treatment for fragile X syndrome is not yet 
available. However, this disorder can be diagnosed by 
molecular analysis of the FMR1 gene mutation. Polymer-
ase chain reaction (PCR)-based DNA analysis of the 
FMR1 gene to detect carriers and the full mutation is 
well established [11,12]. In Caucasian populations, 
approximately 2–6% of males and 2–4% of females 
with nonspecific retardation carry the full fragile X 
mutation [13,14]. The full mutation rate determined 
by molecular testing in the mentally retarded popula-
tion in China is approximately 2.8%, similar to that 
in Caucasian populations [15]. The incidence detected 
by DNA-based screening of the full mutation for non-
specific mental retardation populations is approxi-
mately 1–2% in Western Taiwan [11,16]. However, the 
incidence of fragile X syndrome in mentally retarded 
populations in Eastern Taiwan is not clear.
The aim of this study was to screen for and identify 
individuals with fragile X syndrome using DNA-based 
testing methods at a special education school for the 
mentally retarded in Hualien, Taiwan.
2. Materials and methods
2.1. Subjects
A total of 217 individuals with mental retardation, 
including 148 males (68.2%) and 69 females (31.8%), 
from the National Hualien Special Education School 
for the Mentally Retarded were analyzed for molecular 
identification of fragile X syndrome. The ages of the 
subjects ranged between 6 and 22 years old as shown 
in Table 1. This study was approved by the Institutional 
Review Board of Buddhist Tzu Chi Medical Center 
(IRB092-22) and written informed consents were pro-
vided by the parents or guardians before sampling of 
blood for DNA analysis.
2.2. Genomic DNA preparation and PCR
Genomic DNA was isolated from blood samples using 
a commercial kit (Gentra Systems Inc., Big Lake, MN, 
USA) according to the manufacturer’s instructions. 
The CGG repeat length of FMR1 5’-UTR was analyzed 
by PCR following polyacrylamide gel electrophoresis 
separation.
PCR was performed as described previously [11], 
but with modifications. Briefly, the FMR1 DNA fragment 
was amplified in a volume of 30 μL using genomic DNA 
as template, 1X PCR buffer, 50 μM deoxynucleotide 
triphosphate (dNTP), 100 nM of forward and reverse 
primers, 0.5 M betaine, 10% glycerol, 10% dimethyl 
sulfoxide, and 0.6 U SuperTherm DNA polymerase or 
FastStart Taq DNA polymerase (Roche Applied Science, 
Penzberg, Germany). PCR was carried out for 35 cycles 
in a thermal cycler with 30 seconds of denaturing at 
95°C, 30 seconds of annealing at 64°C, a 1-minute 
extension at 72°C, and a 10-minute final extension step 
to complete the reaction at 72°C. The PCR products 
from male genomic DNA were analyzed by 6% poly-
acrylamide gel electrophoresis followed by ethidium 
bromide staining and ultraviolet detection.
2.3. Southern blot analysis
Southern blot analysis to verify FMR1 gene methylation 
was performed using protocols with a non-radioactive 
chemiluminescent assay as described in a previous 
report [11]. Genomic DNA was digested with restriction 
enzymes, EcoRI and NruI, and separated by 0.8% 
agarose gel electrophoresis. DNA was transferred onto 
the nylon membrane and hybridized with a digoxigenin-
labeled probe. After 24 hours of hybridization, the 
blot was washed with 0.5 × SSC containing 0.1% SDS 
at 60°C, and the DNA band was detected by incubating 
Table 1 — Molecular testing for fragile X syndrome 
in subjects with mental retardation from a special 
education school
 Males Females Total
 (n = 148) (n = 69) (n = 217)
Age range, yr 6–21 6–22 6–22
Molecular testing by PCR 127 0 127
Molecular testing by 23 69 92
 Southern blot analysis
Full mutation of FMR1 gene 2 (1.35%) 1 (1.44%) 3 (1.38%)
Premutation of FMR1 gene 0 0 0
PCR = polymerase chain reaction.
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the blot with the chemiluminescent reagent (Roche 
Applied Science) followed by radiographic film exposure 
for 4 hours.
3. Results
3.1. Molecular screening of males for 
FMR1 gene mutation by PCR
Table 1 summarizes the results of molecular testing 
for fragile X syndrome in this study. A total of 148 
males with mental retardation from a special educa-
tion school were analyzed for fragile X syndrome. 
PCR was performed clearly in 127 out of 148 males, 
and 21 individuals had ambiguous results on the 
molecular testing. The normal CGG repeat size in 
the FMR1 gene was below 54 and could be detected 
in the range of 200–300 bp of PCR products followed 
by 6% polyacrylamide gel electrophoresis (Fig. 1A, 
lanes 2 and 3). The results were normal in 125 out 
of 127 males with PCR followed by DNA gel electro-
phoresis in this study. DNA amplification could not 
be performed well by DNA polymerase for full muta-
tions of the FMR1 gene because the repeating length 
was more than 200 CGG repeats. Fig. 1 shows that 
undetectable PCR products in two out of 127 males 
may have been affected by full mutation of the FMR1 
gene (Fig. 1A, lanes 4 and 5, with undetectable DNA 
bands in the range of normal CGG repeat size).
To rule out unqualified DNA templates leading to 
undetectable DNA products during PCR, another PCR 
of the dystrophin gene was performed as a reaction 
control, and the dystrophin DNA could be detected 
on the gel, as expected, in the two affected males 
(Fig. 1B, lanes 2 and 3, compared with Fig. 1A, lanes 
4 and 5). The results show that the two boys had 
fragile X syndrome.
3.2. Southern blot analysis of affected 
males and all females for verifying 
full mutation of FMR1 gene
To verify the mutation type and carriers of fragile X 
syndrome, all 69 females with mental retardation 
and 23 males, including 21 males with ambiguous 
diagnosis on PCR analysis and two affected individu-
als with undetectable PCR products as described 
previously (Fig. 1A), were analyzed using the Southern 
blot technique (Table 1). In unaffected individuals 
with fragile X full mutation, one single hybridizing 
band of 2.8 kb with a normal range of CGG repeats 
was detected in males and one further band of 5.2 kb 
was detected in females due to X chromosome inac-
tivation (Fig. 2A, lanes 1 and 4). The affected individual 
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Fig. 1 — Examples of polymerase chain reaction (PCR) 
amplification results of the FMR1 gene. PCR DNA prod-
ucts analyzed by 6% polyacrylamide gel electrophoresis. 
(A) PCR products of the FMR1 gene. Lane 1 = 100-bp 
DNA marker; lane 2 = CGG-repeated DNA control marker; 
lane 3 = 52 CGG-repeat positive control; lane 6 = negative 
control. Arrows indicate the size of CGG-repeated DNA 
control marker numbers with 29- (lower), 40- (middle), 
and 52-CGG (upper) repeats. The PCR products of two 
affected male DNA samples (full mutation) are undetect-
able in lanes 4 and 5. (B) PCR products of the dystrophin 
gene. Lane 1 = DNA marker; lanes 2 and 3 = DNA samples 
from the two affected males (full mutation); lane 4 = normal 




























Fig. 2 — Southern blot analysis of the FMR1 gene from 
three affected individuals. (A) Hybridization result from the 
two affected boys. Lanes 1 and 4 = normal controls; lanes 
2 and 3 = full mutation. (B) Hybridization result from the 
one affected girl. Lanes 1 and 3 = normal controls; lane 
2 = full mutation.
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5.9 kb—due to hypermethylation and repeat expansion 
of the FMR1 gene. Fig. 2A shows that only the two 
affected males identified by PCR testing showed hy-
permethylated bands on Southern hybridization 
analysis (Fig. 2A, lanes 2 and 3). This result confirmed 
the PCR data and indicated that two of these 148 males 
(1.35%) with mental retardation had full mutation of 
the FMR1 gene.
One of the 69 females (1.44%) tested was identified 
as having the full mutation. Fig. 2B shows that the 
affected female has one normal allele (lane 2, 2.8 kb 
and 5.2 kb bands) and one methylated allele with 
smear bands of full mutation (lane 2, bands > 5.2 kb). 
A total of 217 individuals with mental retardation were 
screened with PCR and Southern blot analysis, and 
three (1.38%), including two males and one female, 
were identified to have fragile X full mutation.
3.3. The families of individuals with 
fragile X full mutation
Genetic counseling of these affected families was 
performed after verification of the full mutation of 
the FMR1 gene. The three individuals with fragile X 
syndrome belonged to two different families. Two 
affected individuals with fragile X full mutation in 
this screening, one boy and girl, were siblings. Another 
brother with fragile X syndrome was also found in 
the same family. The other affected male belonged 
to a different family but had another fragile X sister. 
The mutated FMR1 gene was inherited from the 
mothers in all the affected individuals.
4. Discussion
In the present study, 217 mentally retarded children 
in Hualien were screened by molecular testing methods 
and three (1.38%) were identified to have full mutation 
of the FMR1 gene. The frequency of fragile X syn-
drome in mentally retarded children in Hualien in 
Eastern Taiwan was 1.38% in this study, very close 
to that in previous reports of Western Taiwan [16].
It has been reported that the prevalence of fragile 
X syndrome in the Caucasian mentally retarded pop-
ulation from molecular screening is 2.6–8.7% in males 
and 2.9–5.4% in females. In Asian populations, mo-
lecular testing in Japanese and Chinese mentally 
retarded subjects gave prevalences of 0.8–2.7% and 
2.8–6.8%, respectively [14,15,17]. In Taiwan, molecular 
screening of children with mental retardation gave 
prevalences ranging from 1.5% to 2.5% [11,16,18]. 
The incidence in this study is lower than that in China 
[11,15,19].
No individual with premutation of the FMR1 gene 
was found in our study. It has been reported that the 
frequency of fragile X syndrome in female carriers is 
very low in the Taiwanese population [18,20,21]. The 
frequency of female carriers is high in Israel (1 in 113), 
and ranges from 1 in 186 to 1 in 259 in the United 
States, Finland and Canada [22–24]. These studies 
indicate that mutation of the FMR1 gene in Taiwanese 
populations may not be as common as in Caucasians.
In this study, the affected individuals belonged to 
two different families and appropriate genetic coun-
seling was provided after molecular detection of fragile 
X syndrome. To date, no treatment is available for this 
disorder, but it can be prevented by genetic counseling 
and prenatal diagnosis. Diagnosis of fragile X syn-
drome among mentally retarded children by DNA-
based screening methods is a practical approach. Early 
diagnosis, appropriate rehabilitation programs, car-
rier detection, genetic counseling and education are 
important issues for managing fragile X syndrome, 
especially in Eastern Taiwan.
In conclusion, we established a molecular diagnosis 
approach to screen mentally retarded children in 
Hualien for fragile X syndrome and reported the inci-
dence of full mutation of the FMR1 gene among 
these children. The continuing education of health 
supervisors in schools for the mentally handicapped 
and follow-up of families with appropriate genetic 
counseling will continue in the future.
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